Giorgio Parmiani

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  2. doi request reprint Autologous versus allogeneic cell-based vaccines?
    Giorgio Parmiani
    Unit of Immuno biotherapy of Melanoma and Solid Tumors, San Raffaele Foundation Scientific Institute, Milan, Italy
    Cancer J 17:331-6. 2011
  3. ncbi request reprint Universal and stemness-related tumor antigens: potential use in cancer immunotherapy
    Giorgio Parmiani
    Department of Oncology, San Raffaele Scientific Institute, Italy
    Clin Cancer Res 13:5675-9. 2007
  4. ncbi request reprint Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells
    Licia Rivoltini
    Unit of Immunotherapy of Human Tumor, Gastrointestinal and Liver Surgery Unit, and Colorectal Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 171:3467-74. 2003
  5. doi request reprint Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells
    Michela Perego
    Department of Experimental Oncology, Fondazione IRCSS, Istituto Nazionale dei Tumori, Milan, Italy
    J Invest Dermatol 130:1877-86. 2010
  6. ncbi request reprint Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:4450-60. 2006
  7. ncbi request reprint Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors and Unit of Medical Statistics and Biometry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 25:2546-53. 2007
  8. doi request reprint LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites
    Chiara Camisaschi
    Unit of Immunotherapy of Human Tumors, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 184:6545-51. 2010
  9. ncbi request reprint Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes
    Roberta Valenti
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:9290-8. 2006
  10. ncbi request reprint Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:3942-9. 2005

Detail Information

Publications85

  1. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  2. doi request reprint Autologous versus allogeneic cell-based vaccines?
    Giorgio Parmiani
    Unit of Immuno biotherapy of Melanoma and Solid Tumors, San Raffaele Foundation Scientific Institute, Milan, Italy
    Cancer J 17:331-6. 2011
    ....
  3. ncbi request reprint Universal and stemness-related tumor antigens: potential use in cancer immunotherapy
    Giorgio Parmiani
    Department of Oncology, San Raffaele Scientific Institute, Italy
    Clin Cancer Res 13:5675-9. 2007
  4. ncbi request reprint Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells
    Licia Rivoltini
    Unit of Immunotherapy of Human Tumor, Gastrointestinal and Liver Surgery Unit, and Colorectal Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 171:3467-74. 2003
    ....
  5. doi request reprint Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells
    Michela Perego
    Department of Experimental Oncology, Fondazione IRCSS, Istituto Nazionale dei Tumori, Milan, Italy
    J Invest Dermatol 130:1877-86. 2010
    ....
  6. ncbi request reprint Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:4450-60. 2006
    ....
  7. ncbi request reprint Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors and Unit of Medical Statistics and Biometry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 25:2546-53. 2007
    ....
  8. doi request reprint LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites
    Chiara Camisaschi
    Unit of Immunotherapy of Human Tumors, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 184:6545-51. 2010
    ..Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites...
  9. ncbi request reprint Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes
    Roberta Valenti
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:9290-8. 2006
    ..Therapeutic interventions on the crucial steps of this pathway may contribute to restore tumor/immune system interactions favoring T-cell-mediated control of tumor growth in cancer patients...
  10. ncbi request reprint Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:3942-9. 2005
    ..Altogether, these findings identify the activation of the NK compartment as an additional immunologic effect of autologous tumor-derived HSP96 administration in cancer patients...
  11. ncbi request reprint Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines
    Andrea Anichini
    Human Tumor Immunobiology and Tumor Immunotherapy Units, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 171:2134-41. 2003
    ....
  12. ncbi request reprint Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer
    Chiara Castelli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133, Milan, Italy
    Cancer Immunol Immunother 53:227-33. 2004
    ..The immunological properties of these proteins and their implications for vaccine in human cancer will be discussed. Immunological and clinical data of phase I/II studies in melanoma and colorectal cancer patients will be reviewed...
  13. ncbi request reprint Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens
    Diego Tosi
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 172:5363-70. 2004
    ..Together, our data suggest that the ability of IFN-DCs to efficiently prime anti-tumor CD8(+) T lymphocytes relied mostly on the positive cross-talk occurring between DCs and NK cells upon stimulation with IFN-alpha...
  14. pmc Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
    Chiara Camisaschi
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133, Milan, Italy
    Cancer Immunol Immunother 62:897-908. 2013
    ..Despite the Treg expansion that was observed in this study, low-dose IL-2 is not detrimental to the functional activities of vaccine-primed CD8(+) T cell effectors when used in the inflammatory environment of vaccination...
  15. doi request reprint Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 18:6485-96. 2012
    ....
  16. ncbi request reprint NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 13:7459-68. 2007
    ..The role of NKG2D receptor in antitumor immunosurveillance has not been completely clarified. We addressed this issue by investigating the involvement of this receptor in tumor-specific immunologic response in melanoma patients...
  17. ncbi request reprint Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide
    Manuela Iero
    Unit of Immunotherapy of Human Tumors, IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
    Cancer Immunol Immunother 56:1979-91. 2007
    ....
  18. doi request reprint TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors
    Cristina Maccalli
    Unit of Immuno biotherapy of Melanoma and Solid Tumors, Department of Molecular Oncology, San Raffaele Scientific and University Institute, Via Olgettina 58, Milan, Italy
    Cancer Immunol Immunother 58:801-8. 2009
    ....
  19. ncbi request reprint Heat shock proteins and their use as anticancer vaccines
    Giorgio Parmiani
    Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 10:8142-6. 2004
  20. doi request reprint CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma
    Viviana Vallacchi
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 68:715-23. 2008
    ..Together, these data indicate a role for CCN3 in melanoma cell interaction with the ECM by regulating integrin expression, resulting in altered cell adhesion and leading melanoma progression to aggressive disease...
  21. ncbi request reprint Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype
    Marialuisa Sensi
    Units of Immunobiology of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy
    Cancer Res 65:632-40. 2005
    ....
  22. ncbi request reprint Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma
    Roberta Mortarini
    Human Tumors Immunobiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, 20133, Italy
    Cancer Res 63:2535-45. 2003
    ....
  23. ncbi request reprint Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients
    Maria Daniotti
    Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Cancer 120:2439-44. 2007
    ..In conclusion, this method can be utilized for monitoring the disease in stage IV melanoma patients but it appears unsatisfactory for the early detection of melanoma...
  24. ncbi request reprint Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape
    Veronica Huber
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Gastroenterology 128:1796-804. 2005
    ....
  25. doi request reprint Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes
    Vincenzo Russo
    Division of Molecular Oncology, Unit of Cancer Gene Therapy, Program in Immunology and Bio Immunotherapy and Gene Therapy of Cancer, San Raffaele Scientific Institute, Milan, Italy
    Int J Cancer 132:2557-66. 2013
    ....
  26. doi request reprint Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes
    Arianna Calcinotto
    Cellular Immunology Unit, San Raffaele Scientific Institute, Milan, Italy
    Cancer Res 72:2746-56. 2012
    ..Furthermore, they illustrate the potential of PPIs to safely correct T-cell dysfunction and improve the efficacy of T-cell-based cancer treatments...
  27. doi request reprint PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells
    Luisa Novellino
    Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cell Signal 20:872-83. 2008
    ....
  28. ncbi request reprint Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen
    Luisa Novellino
    Unit of Immunotherapy of Human Tumors and Unit of Molecular Mechanisms of Tumor Growth and Progression, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 170:6363-70. 2003
    ..These findings further support the relevance of CD4(+) T cells directed against mutated epitopes in tumor immunity and provide the rationale for a possible usage of mutated, tumor-specific Ags for immunotherapy of human cancer...
  29. ncbi request reprint T-cell response to unique and shared antigens and vaccination of cancer patients
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Immun 2:6. 2002
    ..Thus, it is likely that the subgroup of metastatic patients with a high frequency of anti-melanoma memory T cells may not show a clinical response to vaccination...
  30. ncbi request reprint Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
    Licia Rivoltini
    Units of Human Tumor Immunotherapy and Immunobiology, Istituto Nazionale Tumori, Milan, Italy
    Immunol Rev 188:97-113. 2002
    ..Finally, we discuss the role of inducible nitric oxide synthases in determining the inhibition of apoptosis in melanoma cells, which can make such tumor cells resistant to the T-cell attack...
  31. ncbi request reprint Tumor-released microvesicles as vehicles of immunosuppression
    Roberta Valenti
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 67:2912-5. 2007
    ..These findings underscore an important role for these extracellular organelles in remodeling tumor-stromal interactions to promote malignancy...
  32. doi request reprint Follow-up of melanoma: a survey of Italian hospitals
    Alessandro Testori
    Divisione Melanoma e Sarcomi Muscolo Cutanei, Istituto Europeo di Oncologia, Milan, Italy alessandro testori ieo it
    Dermatology 226:32-8. 2013
    ..40%); brain CT/NMR use increases from 51 to 64% and is more common in high-volume centers (p = 0.03). Lymph node echography is more common in high-volume centers (56 vs. 39%, p = 0.03)...
  33. ncbi request reprint Heat shock proteins gp96 as immunogens in cancer patients
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Int J Hyperthermia 22:223-7. 2006
    ....
  34. doi request reprint Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group
    Alessandro Testori
    Istituto Europeo di Oncologia, Milan, Italy
    J Clin Oncol 26:955-62. 2008
    ....
  35. ncbi request reprint Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
    Filiberto Belli
    Unit of General Surgery 2, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 20:4169-80. 2002
    ....
  36. ncbi request reprint Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
    Massimo Di Nicola
    Cristina Gandini Bone Marrow Transplantation Unit, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 10:5381-90. 2004
    ....
  37. pmc The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    J Transl Med 6:8. 2008
    ..Here, we report the main issues discussed during the meeting...
  38. ncbi request reprint Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Natl Cancer Inst 94:805-18. 2002
    ....
  39. ncbi request reprint Unique human tumor antigens: immunobiology and use in clinical trials
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori Foundation, Milan, Italy
    J Immunol 178:1975-9. 2007
    ....
  40. pmc Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy
    Tonia Mazzarella
    Unit of Immuno biotherapy of Melanoma and Solid Tumors, Division of Molecular Oncology, San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy
    Cancer Immunol Immunother 61:1169-82. 2012
    ..Thus, anti-tumor circulating PBMC-derived T cells could be efficiently isolated from melanoma patients by our novel ex vivo enrichment protocol. This protocol appears suitable for ACT studies of cutaneous and ocular melanoma patients...
  41. doi request reprint Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT
    Maria Daniotti
    Melanoma Genetics, Department of Experimental Oncology, Immunotherapy of Human Tumors Unit, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Invest Dermatol 129:1759-68. 2009
    ..BRAF(V600E) mutation occurred at a similar rate (approximately 50%) in lesions from pediatric and familial patients, whereas no NRAS mutations were detected...
  42. ncbi request reprint Melanoma immunology: past, present and future
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori Foundation, Milan, Italy
    Curr Opin Oncol 19:121-7. 2007
    ..This paper aims to evaluate the last three decades of research in melanoma immunotherapy and to provide insights in the future of this strategy...
  43. pmc Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients
    Elena Tassi
    Tumor Immunology Unit, San Raffaele Scientific Institute, Milan, Italy
    PLoS ONE 4:e7234. 2009
    ..Aim of this study was to evaluate whether the Th2 polarization of CEA-specific CD4(+) T cells from pancreatic cancer patients is stable or can be reverted by immunomodulating cytokines...
  44. ncbi request reprint Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors
    Seyed Amir Jalali
    Unit of Immuno biotherapy of Melanoma and Solid Tumors, Division of Molecular Oncology, San Raffaele Scientific Institute, Milan, Italy
    Recent Pat Biotechnol 5:108-17. 2011
    ..In this article, we also used some of the recent patents describing different inventions related to pre-clinical and clinical aspects of peptide based vaccines against human solid tumors...
  45. pmc Immunobiological characterization of cancer stem cells isolated from glioblastoma patients
    Tiziano Di Tomaso
    Department of Pathology, San Raffaele Foundation Scientific Institute, Milan, Italy
    Clin Cancer Res 16:800-13. 2010
    ..The aims of this study were the immunobiological characterization of GBM CSCs and the assessment of whether these cells represent suitable targets for immunotherapy...
  46. ncbi request reprint The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Tumori 94:179-81. 2008
    ..This article briefly summarizes the history and objectives of NIBIT, along with the actions so far taken by the Network...
  47. ncbi request reprint Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells
    Piero Dalerba
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:2321-9. 2005
    ..Taken together, our data show that, in a least subset of CRC, biochemical pathways involved in maintenance of telomere length, such as telomerase, are not activated in a constitutive way in all tumor cells...
  48. ncbi request reprint What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003
    Maria Rescigno
    Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
    Melanoma Res 14:241-3. 2004
    ..This report briefly summarizes some of the highlights and themes of this session...
  49. doi request reprint Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1
    Cristina Maccalli
    Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Italy
    Clin Cancer Res 14:7292-303. 2008
    ..Here, we evaluated whether a specific T-cell-mediated response directed against this molecule can occur in colorectal cancer patients...
  50. ncbi request reprint Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs
    Francesca Luciani
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Nazionale dei Tumori, Milan, Italy
    J Natl Cancer Inst 96:1702-13. 2004
    ....
  51. doi request reprint Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy
    Arianna Calcinotto
    Cellular Immunology Unit, San Raffaele Scientific Institute, 20132 Milan, Italy
    J Immunol 188:2687-94. 2012
    ..Thus, these findings might be relevant for the design of novel immunotherapeutic approaches for cancer patients...
  52. ncbi request reprint Vaccine therapy of cancer
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, National Cancer Institute, Milan, Italy
    Suppl Tumori 1:S28. 2002
  53. ncbi request reprint Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma
    Roberto Luksch
    Department of Medical Oncology, Pediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 89:263-8. 2003
    ..An additional aim was to assess whether any correlation between the immune modifications and the clinical outcome could be found...
  54. doi request reprint Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
    Andrea Volonté
    Unit of Immuno biotherapy of Melanoma and Solid Tumors, San Raffaele Foundation Centre, 20132 Milan, Italy
    J Immunol 192:523-32. 2014
    ..Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients. ..
  55. doi request reprint Surgical treatment of melanoma: a survey of Italian hospitals
    Alessandro Testori
    Divisione Melanoma e Sarcomi Muscolo Cutanei, Istituto Europeo di Oncologia, Milan, Italy alessandro testori ieo it
    Dermatology 226:28-31. 2013
    ..More high-volume centers were organized to perform sentinel node biopsy (91 vs. 56%). There were no major differences between high- and low-volume centers concerning the surgical approach to stage III and IV disease...
  56. ncbi request reprint A merging duo in melanoma formation
    Monica Rodolfo
    Department of Experimental Oncology Istituto Nazionale Tumori, Milan, Italy
    J Invest Dermatol 125:xii-xiii. 2005
  57. ncbi request reprint Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine
    Marilisa Carsana
    Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Gene Ther 9:243-53. 2002
    ..These results provide evidence for immunological changes, including in situ clonally expanded T cells, in metastases of patients vaccinated with IL-7 gene-transduced cells...
  58. ncbi request reprint Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice
    Francesco Lozupone
    Laboratory of Immunology, Istituto Superiore di Sanita, Rome, Italy
    Eur J Immunol 33:556-66. 2003
    ..Furthermore, this work shows that human tumors/SCID mouse models may be useful in evaluating the in vivo efficacy of adoptive immunotherapies...
  59. ncbi request reprint Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
    Licia Rivoltini
    Istituto Nazionale Tumori, ViaVenezian 1, 20133 Milan, Italy
    Expert Opin Biol Ther 5:463-76. 2005
    ....
  60. ncbi request reprint Immunotherapy of melanoma
    Giorgio Parmiani
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian, 1 20133 Milan, Italy
    Semin Cancer Biol 13:391-400. 2003
    ..or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma...
  61. ncbi request reprint Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells
    Luana Lugini
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Cancer Res 66:3629-38. 2006
    ..Moreover, our data suggest that cannibalism may represent a sort of "feeding" activity aimed at sustaining survival and progression of malignant tumor cells in an unfavorable microenvironment...
  62. ncbi request reprint Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin
    Luana Lugini
    Laboratory of Immunology, Istituto Superiore di Sanita, Rome, Italy
    Lab Invest 83:1555-67. 2003
    ..Moreover, our data suggest that gene therapy or drug treatments aimed at inhibiting actin assembly to the phagosomal membranes may be proposed as a new strategy for the control of tumor aggressiveness...
  63. pmc Phenotypic characterization of human colorectal cancer stem cells
    Piero Dalerba
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 104:10158-63. 2007
    ..These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation...
  64. ncbi request reprint Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen
    Monica Rodolfo
    Units of Melanoma Genetics, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy
    Cancer Res 63:6948-55. 2003
    ..We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy...
  65. ncbi request reprint Immunology and immunotherapy of colorectal cancer
    Piero Dalerba
    Unit of Immunotherapy of Human Tumours, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Crit Rev Oncol Hematol 46:33-57. 2003
    ....
  66. ncbi request reprint NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via Venezian 1, I 20133 Milan, Italy
    Eur J Immunol 33:2033-43. 2003
    ..Taken together these data indicate that the engagement of NKG2D, depending on the expression of its ligands by target cells, can influence the pattern of anti-tumor reactivity by T lymphocytes...
  67. ncbi request reprint Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
    Venkatesh Ramakrishna
    Upstate Inc, Charlottesville, VA 22903, USA
    Int Immunol 15:751-63. 2003
    ..These findings broaden the list of CTL-defined antigens that could lead to the development of multi-epitope vaccines for the treatment of ovarian cancer...
  68. ncbi request reprint Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues
    Matteo G Carrabba
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, 20133 Milan, Italy
    Cancer Res 63:1560-7. 2003
    ....
  69. ncbi request reprint Tumor-infiltrating T cells--friend or foe of neoplastic cells?
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan
    N Engl J Med 353:2640-1. 2005
  70. pmc Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles
    Giovanna Andreola
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale dei Tumori, Milan 20133, Italy
    J Exp Med 195:1303-16. 2002
    ..Such vesicles may form a sort of front line hindering lymphocytes and other immunocompetent cells from entering neoplastic lesions and exert their antitumor activity...
  71. pmc Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function
    Paola Matarrese
    Department of Ultrastructures, Istituto Superiore di Sanita, Rome Italy
    Am J Pathol 160:1507-20. 2002
    ....
  72. ncbi request reprint Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
    Michele Maio
    Cancer Bioimmunotherapy Unit and Division of Anesthesia, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, via Pedemontana Occ le, 12, Aviano, 33081 Italy
    Cancer Immunol Immunother 51:9-14. 2002
    ....
  73. ncbi request reprint Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer
    Vincenzo Mazzaferro
    Units of Hepatobiliary and Gastro Pancreatic Surgery, Istituto Nazionale per lo Studio e la Cura Tumori, 20133 Milan, Italy
    Clin Cancer Res 9:3235-45. 2003
    ..Feasibility, safety, and possible clinical benefits were also evaluated...
  74. ncbi request reprint Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial
    Massimo Di Nicola
    Cristina Gandini Bone Marrow Transplantation Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan I 20133, Italy
    Hum Gene Ther 14:1347-60. 2003
  75. ncbi request reprint International meeting "Immunotherapy of cancer: challenges and needs"
    Maria Ferrantini
    Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Cancer Immunol Immunother 56:581-5. 2007
    ....
  76. ncbi request reprint Vaccination: role in metastatic melanoma
    Lorenzo Pilla
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Unit of Immunotherapy of Human Tumors, Via Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 6:1305-18. 2006
    ....
  77. ncbi request reprint T cell infiltration and prognosis in HCC patients
    Giorgio Parmiani
    J Hepatol 45:178-81. 2006
  78. ncbi request reprint Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors
    Tiziana Di Pucchio
    Section of Experimental Immunotherapy, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Rome, Italy
    Cancer Res 66:4943-51. 2006
    ....
  79. ncbi request reprint Chemokine receptor 7, a new player in regulating apoptosis of CD8+ T cells in cancer patients
    Giorgio Parmiani
    Clin Cancer Res 11:7587-8. 2005
  80. ncbi request reprint A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 55:958-68. 2006
    ..Clinical activity was limited to SD. However, both immunological and clinical responses were not improved as compared with those recorded in a previous study investigating HSPPC-96 monotherapy...
  81. ncbi request reprint International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
    Filippo Belardelli
    Istituto Superiore di Sanita, Rome, Italy
    Cancer Res 64:6827-30. 2004
    ..An entire session was devoted to the use of dendritic cells for the development of cancer vaccines. The results of clinical studies and the advantages of using new modalities for preparing dendritic cell-based vaccines were discussed...
  82. ncbi request reprint A listing of human tumor antigens recognized by T cells: March 2004 update
    Luisa Novellino
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 54:187-207. 2005
    ..Overall, the updated list is a database tool for clinicians, scientists and students who have an interest in the field of tumor immunology and immunotherapy...
  83. ncbi request reprint BRAF alterations are associated with complex mutational profiles in malignant melanoma
    Maria Daniotti
    Unit of Melanoma Genetics, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Oncogene 23:5968-77. 2004
    ....
  84. ncbi request reprint Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice
    Francesco Lozupone
    Laboratories of Immunology and Virology, Istituto Superiore di Sanita, Rome, Italy
    Cancer Res 64:378-85. 2004
    ..Moreover, our study emphasizes the usefulness of human tumor/SCID mouse models for preclinical evaluation of immunotherapy protocols against human tumors...
  85. ncbi request reprint Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation
    Chiara Casati
    Unit of Immunotherapy of Human Tumor, Fondazione Instituto di Ricerca e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milano, Italy
    J Immunol 180:3782-8. 2008
    ..Altogether, these data show for the first time a role of LAG-3 in mediating dendritic cell activation when expressed on the T cell surface or released after specific Ag stimulation in the interspaces of immunological synapses...